Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PROSPECTIVE MULTICENTER STUDY OF THYROID-CARCINOMA TREATMENT - INITIAL ANALYSIS OF STAGING AND OUTCOME
Autore:
SHERMAN SI; BRIERLEY JD; SPERLING M; AIN KB; BIGOS ST; COOPER DS; HAUGEN BR; HO MN; KLEIN I; LADENSON PW; ROBBINS J; ROSS DS; SPECKER B; TAYLOR T; MAXON HR;
Indirizzi:
UNIV TEXAS,MD ANDERSON CANCER CTR,SECT ENDOCRINE NEOPLASIA & HORMONALDISORDERS HOUSTON TX 77030 PRINCESS MARGARET HOSP,DEPT RADIAT ONCOL TORONTO ON M4X 1K9 CANADA UNIV CINCINNATI,MED CTR,DEPT NUCL MED CINCINNATI OH 45267 UNIV KENTUCKY,MED CTR,DEPT MED LEXINGTON KY 40536 MAINE MED CTR,DEPT MED PORTLAND ME 04102 SINAI HOSP,DEPT MED BALTIMORE MD 21215 UNIV COLORADO,HLTH SCI CTR,DEPT MED DENVER CO 80262 N SHORE UNIV HOSP,DEPT MED MANHASSET NY 11030 JOHNS HOPKINS UNIV,SCH MED,DEPT MED BALTIMORE MD 21205 NIDDK,GENET & BIOCHEM BRANCH,NIH BETHESDA MD 20892 MASSACHUSETTS GEN HOSP,THYROID UNIT BOSTON MA 02114 S DAKOTA STATE UNIV,MARTIN PROGRAM HUMAN NUTR BROOKINGS SD 57007 BAYER PHARMACEUT NEW HAVEN CT 06511
Titolo Testata:
Cancer
fascicolo: 5, volume: 83, anno: 1998,
pagine: 1012 - 1021
SICI:
0008-543X(1998)83:5<1012:PMSOTT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROGNOSTIC SCORING SYSTEM; PAPILLARY; CANCER; SURVIVAL;
Keywords:
THYROID NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; COMPARATIVE STUDY; PROSPECTIVE STUDIES; PAPILLARY CARCINOMA; FOLLICULAR CARCINOMA; MEDULLARY CARCINOMA; ANAPLASTIC CARCINOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
S.I. Sherman et al., "PROSPECTIVE MULTICENTER STUDY OF THYROID-CARCINOMA TREATMENT - INITIAL ANALYSIS OF STAGING AND OUTCOME", Cancer, 83(5), 1998, pp. 1012-1021

Abstract

BACKGROUND. A novel prognostic staging classification encompassing all forms of thyroid carcinoma was created for the National Thyroid Cancer Treatment Cooperative Study (NTCTCS) Registry, with the goal of prospective validation and comparison with Other available staging classifications. METHODS. Patient information was recorded prospectively from 14 institutions. Clinicopathologic staging was based on patient age at diagnosis, tumor histology, tumor size, intrathyroidal multifocality, extraglandular invasion, metastases, and tumor differentiation. RESULTS. Between 1987 and 1995, 1607 patients were! registered. Approximately 43% of patients were classified as NTCTCS Stage I, 24% Stage II, 24% Stage III, and 9% Stage IV. Patients with follicular carcinoma were mc,re likely to have ''high risk'' Stage III or IV disease than those with papillary carcinoma. Of 1562 patients for whom censored follow-up was available (median follow-up, 40 months), 78 died of thyroid carcinoma or complications of its treatment. I:ive-year product-limit patient disease specific survival was 99.8% for Stage I, 100% for Stage II, 91.9% for Stage III, and 48.9% for Stage TV (P < 0.0001). The frequency of remaining disease free also declined significantly with increasing stage (94.3% for Stage I, 93.1% for Stage II, 77.8% for Stage III, and 24.6% for Stage nr). The same patients also were staged applyingsix previously published classifications as appropriate for their tumor type. The predictive value of the NTCTCS Registry staging classification consistently was among the highest for disease specific mortality and for remaining disease free, regardless of the tumor type. CONCLUSIONS. The NTCTCS Registry staging classification provides a prospectively validated scheme for predicting short term prognosis for patientswith thyroid carcinoma. [See editorial counterpoint on pages 844-7 and reply to counterpoint on pages 848-50, this issue.] (C) 1998 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 06:36:53